Previous findings from the reported literature as well as findings from our study direct towards potentially substantial evidence of related elevated expression of HIF-1α, MDR1 and LAPTM4B as an indicator of tumor progression, higher tumor stage and resistance to chemotherapy in breast, ovarian, colon and prostate cancer. Here, HIF1A is linked to prostate carcinoma.